Comparison of the prognostic value of different inflammation-based scores in patients with hepatocellular carcinoma after Lenvatinib therapy

Table 1 Baseline characteristics of the enrolled patients

Variables	n = 144
Age, year	52 (21-75)
Gender (male/female)	126/18 (87.5/12.5)
Hepatitis (yes/no)	128/16 (88.9/11.1)
ALT, U/L, (>/≤ 50)	64/80 (44.4/55.6)
AST, U/L, (>/≤ 40)	117/27 (81.3/18.7)
ALB, g/L, (>/≤ 35)	125/19 (86.8/13.2)
TBIL, µmol/L, (>/≤ 17.1)	62/82 (43/57)
Largest tumor size, cm	11.65 (1.2-23.1)
Tumor number (> 1/1)	109/35 (75.7/24.3)
Macrovascular invasion (yes/no)	102/42 (70.8/29.2)
Lymph node metastasis (yes/no)	39/105 (27/73)
Metastasis (yes/no)	27/117 (18.7/81.3)
TNM stage (III-IV/II)	125/19 (86.8/13.2)
CRP, mg/L (> 7.9/≤ 7.9)	100/44 (69.4/30.6)
PLR (1/0)	19/125 (13.2/86.8)
NLR (1/0)	73/71 (50.7/49.3)
LCR (1/0)	110/34 (76.4/23.6)
LMR (1/0)	89/55 (61.8/38.2)
SII (1/0)	78/66 (54.2/45.8)
CAR (1/0)	101/43 (70.1/29.9)
PNI (1/0)	71/73 (49.3/50.7)

Values are presented as median (range) or n (%). ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALB: Albumin; TBIL: Total bilirubin; TNM: Tumor-node-metastasis; CRP: C-reactive protein; PLR: Platelet-to-lymphocyte ratio; NLR: Neutrophil-to-lymphocyte ratio; LCR: Lymphocyte-to-C-reactive protein ratio; LMR: Lymphocyte-to-monocyte ratio; SII: Systemic immune-inflammation index; CAR: C-reactive protein-to-albumin ratio; PNI: Prognostic nutritional index.